Marshall Wace North America L.P. trimmed its position in shares of Imperva Inc (NASDAQ:IMPV) by 24.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 423,937 shares of the software maker’s stock after selling 136,450 shares during the period. Marshall Wace North America L.P. owned about 1.20% of Imperva worth $19,692,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado increased its stake in Imperva by 142.6% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 2,608 shares of the software maker’s stock worth $121,000 after purchasing an additional 1,533 shares during the period. Royal Bank of Canada increased its stake in Imperva by 99.4% in the 1st quarter. Royal Bank of Canada now owns 2,794 shares of the software maker’s stock worth $122,000 after purchasing an additional 1,393 shares during the period. Aperio Group LLC purchased a new position in Imperva in the 2nd quarter worth approximately $203,000. Oppenheimer & Co. Inc. purchased a new position in Imperva in the 2nd quarter worth approximately $222,000. Finally, Global Endowment Management LP purchased a new position in Imperva in the 3rd quarter worth approximately $390,000. 93.43% of the stock is currently owned by institutional investors.
NASDAQ IMPV opened at $55.52 on Friday. Imperva Inc has a twelve month low of $37.17 and a twelve month high of $57.65.
A number of equities analysts have commented on the company. BidaskClub cut Imperva from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Zacks Investment Research upgraded Imperva from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a research report on Friday, October 12th. Macquarie lowered Imperva from an “outperform” rating to a “neutral” rating and set a $55.00 price objective on the stock. in a research report on Thursday, October 11th. Morgan Stanley upgraded Imperva from an “underweight” rating to an “equal weight” rating and set a $56.00 price objective on the stock in a research report on Thursday, October 11th. Finally, JPMorgan Chase & Co. upgraded Imperva from an “underweight” rating to a “neutral” rating in a research report on Thursday, October 11th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $56.37.
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.